Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Unicycive Therapeutics is set to announce its earnings results on August 13th, with analysts predicting an earnings per share of ($0.70) for the quarter.
• The company's previous earnings report on May 14th revealed a loss of ($0.50) per share, significantly outperforming the consensus estimate of ($1.40).
• Brokerage firm HC Wainwright has upgraded Unicycive's stock to a "strong-buy" rating with a target price of $90.00.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($1.40) by $0.90. On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock opened at $4.09 on Monday. Unicycive Therapeutics has a fifty-two week low of $2.02 and a fifty-two week high of $11.00. The firm has a 50 day moving average price of $5.53 and a 200 day moving average price of $5.73. The company has a market capitalization of $51.70 million, a PE ratio of -0.80 and a beta of 1.88.

Wall Street Analyst Weigh In

A number of brokerages recently commented on UNCY. HC Wainwright upgraded shares of Unicycive Therapeutics to a "strong-buy" rating and set a $90.00 target price for the company in a research note on Tuesday, May 27th. Guggenheim initiated coverage on shares of Unicycive Therapeutics in a research report on Monday, April 21st. They set a "buy" rating and a $60.00 target price on the stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.